Metolazone - Heart failure

You are here : Home > Formulary Search > Metolazone - Heart failure

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

Restrictions / Comments :

Important

Initiation by specialist. The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand

Documentation

Webpage

Differences-between-metolazone-preparations-and-safety-considerations

PAD Profile

ChemicalSubstance :

Metolazone

Indication :

Heart failure

Group Name :

Keywords :

congestive heart failure, oedema

Brand Names Include :

Xaqua

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Heart failure

Supporting Documents :

Other Indications

Below are listed other indications that Metolazone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Heart failure.

Committee Recommendations (1)

14 Sep 22 - Surrey Heartlands Medicines Safety Committee (MSC)

When initiating patients on metolazone the licensed, branded Xaqua preparation should be prescribed.

Any switch between products should take into account the difference in bioavailability between Xaqua and other available unlicensed products.

Switching from the unlicensed (imported) product to Xaqua may require a reduction in dose by half, or for the same dose to be used but adjust the frequency from daily to alternate days.

The tablets have a single score-line and can be divided into equal halves.

Update March 2023:

Refer any patients who are taking unlicensed metolazone and have not been reviewed to the prescribing specialist for review and consideration for switching to the licensed product Xaqua